表紙
市場調査レポート

自己免疫疾患治療薬と治療法:世界市場

Drugs and Treatments for Autoimmune Diseases: Global Markets

発行 BCC Research 商品コード 219301
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
自己免疫疾患治療薬と治療法:世界市場 Drugs and Treatments for Autoimmune Diseases: Global Markets
出版日: 2011年10月21日 ページ情報: 英文
概要

世界の自己免疫疾患治療市場は2010年に340億米ドルに達しました。今後もCAGR7.2%で拡大し、2011年には389億米ドル、2016年には550億米ドルに成長するとみられています。米国が最大市場で世界市場の43%を占めており、2016年にはシェア44%を保持すると見込まれています。これに続くのが欧州市場で27%のシェアを有しています。2016年には28%となる見通しです。

当レポートでは、自己免疫疾患について概説するとともに、世界の治療薬市場の概要と医薬品別動向、新興の治療薬、法規制、参入企業の概要をまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 自己免疫疾患の概要

  • 自己免疫と自己免疫系
  • ヒトの免疫系
  • 遺伝子学と自己免疫疾患
  • 自己免疫疾患の原因
  • 女性と自己免疫疾患
  • 人種の影響
  • 環境の役割
  • 自己免疫疾患の診断
  • 主要な自己免疫疾患

第4章 自己免疫疾患治療薬市場

  • 関節リウマチ
  • 1型糖尿病
  • 尋常性狼瘡
  • 多発性硬化症
  • 炎症性腸疾患
  • 乾癬
  • その他の自己免疫疾患
  • 自己免疫に関連する疾患

第5章 世界の自己免疫疾患治療薬市場

  • 様々な法規制
  • 自己免疫治療市場の促進因子
  • 米国市場
  • 欧州市場
  • 日本市場
  • その他の諸国
  • 医療制度改革の影響
  • 治療における新興動向
  • 業界の変化

第6章 医薬品別市場

  • 適切な治療薬の種類
  • 腫瘍壊死因子阻害剤
  • B細胞阻害剤
  • T細胞阻害剤
  • インターロイキン阻害剤
  • 免疫抑制剤
  • βインターフェロン
  • インスリン
  • 様々な作用機序をもつその他の薬剤と治療法
  • 他の作用機序
  • 特許の失効
  • 2009年、2010年の新薬承認

第7章 自己免疫診断検査市場

  • 酵素結合免疫吸着剤アッセイ
  • 免疫蛍光アッセイ
  • HLA検査
  • マニュアル検査方法
  • 自動検査方法
  • 現在の自己免疫疾患の診断検査
  • 自己免疫疾患の診断検査市場

第8章 自己免疫治療補助技術

第9章 現在の研究と新興の治療薬

  • 治療用ワクチン
  • スタチン
  • 医薬品
  • 診断検査

第10章 法規制と特許

  • 法規制
  • 特許

第11章 企業ディレクトリ

  • 製薬会社
  • 診断検査会社
  • 補助技術会社

図表

目次
Product Code: HLC091A

Abstract

REPORT HIGHLIGHTS

THIS REPORT CONTAINS:

  • The global market for autoimmune treatments reached at $34 billion in 2010, it is expected to reach at $38.9 billion by 2011 and it will further grow to $55 billion by 2016 at a compounded annual growth rate (CAGR) of 7.2%.
  • U.S being the largest market for autoimmune treatments holds 43% share in the global market, it will sustain its position and will hold 44% market share in 2016.
  • Europe remains the second largest market for autoimmune treatments holds 27% share in the global market, it will sustain its position and will hold 28% market share in 2016.

SUMMARY FIGURE
GLOBAL MARKET FOR AUTOIMMUNE TREATMENTS BY GEOGRAPHICAL AREA,
2011 AND 2016 (%)

Source: BCC Research

REASONS FOR DOING THE STUDY

The objective of this study is to provide an in-depth analysis and forecast of the global autoimmune products market. The focus is on products and therapies currently used or under development for treatment of a variety of autoimmune diseases.

The global market for autoimmune therapeutics was estimated at more than $34 billion in 2010, with mid-single-digit growth through 2016. Different segments such as arthritis and psoriasis treatments are projected to grow at a faster rate than other treatments.

The report will analyze the global markets by region and by disease, and then provide growth projections for each region and/or disease.

STUDY GOALS AND OBJECTIVES

Autoimmune diseases arise from an overactive immune response by the body against substances and tissues normally present in the body. An autoimmune reaction can be triggered by a foreign substance entering the body; an alteration of normal body substances through a virus, drug, sunlight, or radiation; a malfunctioning of cells that control antibody production within the body; and genetic predisposition.

Autoimmune diseases afflict individuals with symptoms presented in the neurological, musculoskeletal, dermatological, and gastrointestinal areas of the body. Women are more likely to have autoimmune disorders than men, and research is ongoing to determine why these diseases target women of all ages.

This report is designed to investigate the autoimmune market by disease and by treatment, with supporting tables and figures to illustrate projected growth. The report will include the U.S., Europe, Japan, and other countries such as China and India.

SCOPOE OF REPORT

This report offers forecasts by product segment, disease, and geographical region from 2011 through 2016, including supporting analyses for projections.

This report is a valuable tool for anyone assessing the autoimmune market and attempting to devise a strategy for successful competition within it. It provides a thorough background on the structure of the autoimmune market and the chief challenges and opportunities it faces. It offers the information necessary for understanding the current market and for addressing the emerging one.

METHODOLOGIES AND INFORMATION SOURCES

Information for this report has been obtained from a variety of primary and secondary research sources, including industry analysts, annual reports, SEC reports, the American Autoimmune Related Diseases Association (AARDA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD), the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), the text Immunology (Lippincott Williams and Wilkins), government agencies outside the U.S., and journal articles. Secondary sources included literature searches, product literature, and press releases.

When precise information was unavailable, a consensus was made using reasonable assumptions and estimates based on historical data.

ANALYST CREDENTIALS

Peggy S. Lehr is the BCC Research Analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder and an MS in Communication from the University of Denver. Ms. Lehr has completed more than 13 reports for BCC, primarily on the medical and pharmaceutical industries. She has worked within the publishing industry for both for-profit and not-for-profit organizations.

Table of Contents

Drugs and Treatments for Autoimmune Diseases: Global Markets

Chapter - 1: INTRODUCTION - Complimentary

  • REASONS FOR DOING THE STUDY
  • STUDY GOALS AND OBJECTIVES
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGIES AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter - 2: SUMMARY

  • Table Summary: GLOBAL MARKET FOR AUTOIMMUNE TREATMENTS, THROUGH 2016
  • Figure Summary: GLOBAL MARKET FOR AUTOIMMUNE TREATMENTS BY GEOGRAPHICAL AREA, 2011 AND 2016

Chapter - 3: OVERVIEW OF AUTOIMMUNE DISEASE

  • AUTOIMMUNITY AND THE AUTOIMMUNE SYSTEM
  • COMPLEX HUMAN IMMUNE SYSTEM
  • GENETICS AND AUTOIMMUNE DISEASES
  • CAUSES OF AUTOIMMUNE DISEASES
  • WOMEN AND AUTOIMMUNE DISEASE
  • AFFECTS ON ETHNIC GROUPS
  • ROLE OF THE ENVIRONMENT
  • DIAGNOSING AUTOIMMUNE DISEASES
  • MAJOR RECOGNIZED AUTOIMMUNE DISEASES

Chapter - 4: MARKET FOR AUTOIMMUNE PHARMACEUTICALS

  • RHEUMATOID ARTHRITIS
  • TYPE 1 DIABETES
  • LUPUS
  • MULTIPLE SCLEROSIS
  • INFLAMMATORY BOWEL DISEASE
  • PSORIASIS
  • OTHER MAJOR AUTOIMMUNE DISEASES
  • RECOGNIZED AUTOIMMUNE AND AUTOIMMUNE-RELATED DISEASES

Chapter - 5: GLOBAL AUTOIMMUNE PHARMACEUTICAL THERAPIES MARKET

  • REGIONAL VARIATIONS
  • DRIVERS OF AUTOIMMUNE TREATMENT MARKET
  • U.S. MARKET
  • EUROPEAN MARKET
  • JAPANESE MARKET
  • REST OF THE WORLD MARKET
  • AFFECTS OF HEALTHCARE REFORM
  • EMERGING TRENDS IN TREATMENTS
  • CHANGES IN THE INDUSTRY

Chapter - 6: AUTOIMMUNE DISEASE PHARMACEUTICAL MARKET BY PHARMACEUTICAL TYPE

  • TYPES OF APPROPRIATE PHARMACEUTICALS
  • TUMOR NECROSIS FACTOR INHIBITORS
  • B-CELL INHIBITORS
  • T-CELL INHIBITORS
  • INTERLEUKIN INHIBITORS
  • IMMUNOSUPPRESSANTS
  • BETA INTERFERONS
  • INSULIN
  • OTHER DRUGS AND THERAPIES WITH DIFFERING METHODS OF ACTION
  • OTHER MECHANISMS OF ACTION
  • PATENT EXPIRATIONS
  • NEW DRUG APPROVALS IN 2009 AND 2010
    • Table 29: GLOBAL MARKET FOR AUTOIMMUNE PHARMACEUTICALS BY TYPE, THROUGH 2016
    • Figure 3: GLOBAL MARKET SHARE FOR AUTOIMMUNE PHARMACEUTICALS BY TYPE, 2011 AND 2016

Chapter - 7: AUTOIMMUNE DIAGNOSTIC TESTING MARKET

  • ENZYME-LINKED IMMUNOSORBENT ASSAY
  • IMMUNOFLUORESCENCE ASSAY
  • HLA TESTING
  • MANUAL TESTING METHODS
  • AUTOMATED TESTING METHODS
  • CURRENT DIAGNOSTIC TESTS FOR AUTOIMMUNE DISEASE
  • MARKET FOR DIAGNOSTIC TESTS FOR AUTOIMMUNE DISEASE

Chapter - 8: AUTOIMMUNE TREATMENT ASSISTIVE TECHNOLOGIES

  • AUTOIMMUNE THERAPIES
  • ASSISTIVE PRODUCTS

Chapter - 9: CURRENT RESEARCH AND EMERGING PHARMACEUTICALS

  • THERAPEUTIC VACCINES
  • STATINS
  • PHARMACEUTICALS
  • DIAGNOSTIC TESTING

Chapter - 10: REGULATIONS AND PATENTS

  • REGULATIONS
  • PATENTS

Chapter - 11: COMPANY DIRECTORY

  • PHARMACEUTICAL COMPANIES
  • DIAGNOSTIC TESTING COMPANIES
  • ASSISTIVE TECHNOLOGY COMPANIES

List of Tables

  • Summary Table: GLOBAL MARKET FOR AUTOIMMUNE TREATMENTS, THROUGH 2016
    • Table 1: INFECTIONS IN HUMANS ASSOCIATED WITH SELECTED AUTOIMMUNE DISEASES
    • Table 2: RECOGNIZED AND POTENTIAL AUTOIMMUNE DISEASES AND THE SYSTEMS THEY EFFECT, 2011
    • Table 3: GLOBAL MARKET FOR PHARMACEUTICAL THERAPIES FOR LEADING AUTOIMMUNE DISEASES, THROUGH 2016
    • Table 4: AMERICAN COLLEGE OF RHEUMATOLOGY RECOMMENDATIONS FOR RA TREATMENTS, 2008
    • Table 5: GLOBAL MARKET FOR RHEUMATOID ARTHRITIS MEDICATIONS, THROUGH 2016
    • Table 6: GLOBAL MARKET FOR TYPE 1 DIABETES PHARMACEUTICAL PRODUCTS, THROUGH 2016
    • Table 7: MAJOR MANUFACTURERS OF DIABETES PRODUCTS, 2011
    • Table 8: PHARMACEUTICAL TREATMENTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY CONDITION TYPE, 2011
    • Table 9: INVESTIGATIONAL TREATMENTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS, 2011
    • Table 10: GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT LUPUS, THROUGH 2016
    • Table 11: PHARMACOLOGICAL TREATMENTS FOR MULTIPLE SCLEROSIS BY NAME, MANUFACTURER, DOSAGE, AND APPROVAL DATE, 2011
    • Table 12: MARKET FOR MS PHARMACEUTICALS, THROUGH 2016
    • Table 13: GLOBAL MARKET FOR IBD MEDICATIONS, THROUGH 2016
    • Table 14: MEDICATIONS TO TREAT ULCERATIVE COLITIS, 2011
    • Table 15: GLOBAL MARKET FOR MEDICATIONS TO TREAT ULCERATIVE COLITIS, THROUGH 2016
    • Table 16: CURRENT MEDICATIONS FOR THE TREATMENT OF CROHN'S DISEASE BY MANUFACTURER, 2011
    • Table 17: GLOBAL MARKET FOR MEDICATIONS TO TREAT CROHN'S DISEASE, THROUGH 2016
    • Table 18: SELECTED CURRENT MEDICATIONS FOR PSORIASIS, 2011
    • Table 19: GLOBAL MARKET FOR PSORIASIS PHARMACEUTICALS, THROUGH, 2016
    • Table 20: RECOGNIZED AUTOIMMUNE AND AUTOIMMUNE-RELATED DISEASES*
    • Table 21: GLOBAL AUTOIMMUNE PHARMACEUTICAL THERAPY MARKET BY REGION, THROUGH 2016
    • Table 22: TOP 10 COUNTRIES IN WHICH MS IS MOST OR LEAST PREVALENT
    • Table 23: U.S. MARKET FOR U.S. AUTOIMMUNE PHARMACEUTICAL THERAPIES, THROUGH 2016
    • Table 24: EUROPEAN MARKET FOR AUTOIMMUNE PHARMACEUTICALS, THROUGH 2016
    • Table 25: APPROVED DMARDS AND BIOLOGICALS FOR TREATMENT OF RA IN JAPAN AND THE U.S., 2009
    • Table 26: JAPANESE MARKET FOR AUTOIMMUNE PHARMACEUTICALS, THROUGH 2016
    • Table 27: REST OF THE WORLD MARKET FOR AUTOIMMUNE PHARMACEUTICALS, THROUGH 2016
    • Table 28: SELECTED MERGERS AND/OR ACQUISITIONS, 2006-2011
    • Table 29: GLOBAL MARKET FOR AUTOIMMUNE PHARMACEUTICALS BY TYPE, THROUGH 2016
    • Table 30: TNF INHIBITORS AVAILABLE IN THE U.S., E.U., AND JAPAN, 2011
    • Table 31: TNF INHIBITORS FOR AUTOIMMUNE DISEASES, 2011
    • Table 32: GLOBAL MARKET FOR TNF INHIBITORS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2016
    • Table 33: B-CELLAND T-CELL INHIBITORS FOR AUTOIMMUNE DISEASES, 2011
    • Table 34: GLOBAL MARKET FOR B-CELL AND T-CELL INHIBITORS, THROUGH 2016
    • Table 35: INTERLEUKIN INHIBITORS FOR AUTOIMMUNE DISEASES, 2011
    • Table 36: MARKET FOR INTERLEUKIN PRODUCTS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2016
    • Table 37: IMMUNOSUPPRESSANTS FOR AUTOIMMUNE DISEASES, 2011
    • Table 38: GLOBAL MARKET FOR IMMUNOSUPPRESSANTS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2016
    • Table 39: BETA INTERFERONS FOR AUTOIMMUNE DISEASES, 2011
    • Table 40: GLOBAL MARKET FOR BETA INTERFERONS, THROUGH 2016
    • Table 41: GLOBAL MARKET FOR INSULIN, THROUGH 2016
    • Table 42: OTHER PHARMACEUTICAL PRODUCTS WITH DIFFERING MECHANISMS OF ACTION TO TREAT AUTOIMMUNE DISEASES, 2011
    • Table 43: MARKET FOR OTHER DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2016
    • Table 44: PATENT EXPIRIES FOR PHARMACEUTICALS TO TREAT AUTOIMMUNE DISEASES, 2007-2018
    • Table 45: NEW DRUG APPROVALS FOR TREATMENT OF AUTOIMMUNE DISEASES, 2009-2011
    • Table 46: LEADING MANUFACTURERS OF AUTOMATED DIAGNOSTIC TESTING EQUIPMENT
    • Table 47: SELECTED MANUFACTURERS OF DIAGNOSTIC TESTS FOR AUTOIMMUNE DISEASES, 2011
    • Table 48: TEST TYPE BY AUTOIMMUNE CONDITION, 2011
    • Table 49: GLOBAL MARKET FOR AUTOIMMUNE DIAGNOSTIC TESTS, THROUGH 2016
    • Table 50: GLOBAL MARKET FOR ASSISTIVE TECHNOLOGIES TO TREAT TYPE 1 DIABETES, THROUGH 2016
    • Table 51: PATENTS BY MANUFACTURER
    • Table 52: PHARMACEUTICAL PATENTS BY DATE OF ISSUE, 2009-2011
    • Table 53: PATENTS BY MANUFACTURER
    • Table 54: PATENT COMPOUNDS FOR AUTOIMMUNE TREATMENTS, 2005-2011
    • Table 55: PATENTS BY INDICATION: RHEUMATOID ARTHRITIS, 2005-2011
    • Table 56: PATENTS BY INDICATION: INFLAMMATORY BOWEL DISEASES, 2005-2011
    • Table 57: PATENTS BY INDICATION: TYPE 1 DIABETES, 2005-2011
    • Table 58: PATENT BY INDICATION: DIAGNOSTIC TESTING AND ASSAYS, 2005-2011

List of Figures

  • Summary Figure: GLOBAL MARKET FOR AUTOIMMUNE TREATMENTS BY GEOGRAPHICAL AREA, 2011 AND 2016
    • Figure 1: GLOBAL MARKET SHARE FOR TYPE 1 DIABETES INSULIN PRODUCTS BY MANUFACTURER, 2011
    • Figure 2: GLOBAL MARKET SHARE FOR AUTOIMMUNE THERAPIES BY REGION, 2011 AND 2016
    • Figure 3: GLOBAL MARKET SHARE FOR AUTOIMMUNE PHARMACEUTICALS BY TYPE, 2011 AND 2016
    • Figure 4: GLOBAL MARKET SHARE FOR TNF PHARMACEUTICAL MARKET BY PRODUCT, 2011
    • Figure 5: GLOBAL MARKET SHARE FOR BLOOD GLUCOSE MONITORS TO TREAT TYPE 1 DIABETES BY MANUFACTURER, 2011
Back to Top